Immitra Bio
Schlieren
About Immitra Bio
At Immitra Bio, we are developing a unique genetic medicine platform that combines two of the most powerful biomedical technologies: hematopoietic stem cells (HSCs) and CRISPR-Cas9 gene editing. Our novel technique allows for precise and long-lasting gene alterations within blood stem cells, resulting in transformational treatments for uncommon diseases with significant unmet medical needs.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Total funding: $111.1K
- Last round: Debt Financing (Feb 2025)
- Website: immitrabio.com
Industries & Categories
Biotechnology, Life Science
Social Profiles
Canonical: https://fsome.com/organization/immitra-bio-36095 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.